文献速递间质性肺疾病呼吸危重症与机械通气

甲氨蝶呤与类风湿关节炎相关间质性肺病

Methotrexate and rheumatoid arthritis associated interstitial lung disease.
PubMed 文献 · Eur Respir J · 2021-02-11

本研究通过病例对照设计及国际重复样本,评估既往甲氨蝶呤(MTX)暴露与类风湿关节炎相关间质性肺病(RA-ILD)的关联。发现样本显示MTX暴露与RA-ILD呈负相关(校正OR 0.46,95%CI 0.24-0.90;p=0.022),重复样本证实(汇总校正OR 0.39,95%CI 0.19-0.79;p=0.009),合并校正OR为0.43(95%CI 0.26-0.69;p=0.0006)。MTX曾用者中RA-ILD患者比例更低,且ILD检出延迟(11.4±10.4年 vs 4.0±7.4年;p<0.001)。

要点

  • MTX暴露与RA-ILD风险降低相关,合并校正OR 0.43(95%CI 0.26-0.69)。
  • MTX曾用者RA-ILD检出时间显著延迟(11.4±10.4年 vs 4.0±7.4年)。
  • 结果不支持MTX增加RA-ILD风险,各HRCT模式一致。

核心结论

  • MTX使用与RA患者RA-ILD风险增加无关,且MTX治疗者ILD检出更晚。

研究设计与样本

  • 病例对照研究,包括发现样本和国际重复样本。
  • 纳入410例RA相关慢性纤维性ILD患者和673例无ILD的RA患者。
  • 采用荟萃分析技术合并不同样本的估计值。

主要发现

  • 发现样本中MTX暴露与RA-ILD呈负相关(校正OR 0.46,95%CI 0.24-0.90;p=0.022)。
  • 重复样本证实负相关(汇总校正OR 0.39,95%CI 0.19-0.79;p=0.009)。
  • 合并发现和验证样本的校正OR为0.43(95%CI 0.26-0.69;p=0.0006)。
  • MTX曾用者在RA-ILD患者中比例低于无ILD者,与胸部高分辨率CT模式无关。
  • RA-ILD患者中,MTX曾用者ILD检出显著延迟(11.4±10.4年 vs 4.0±7.4年;p<0.001)。

临床怎么用

  • 对于RA患者,MTX使用不增加RA-ILD风险,可支持其作为锚定药物的使用。
  • MTX治疗者ILD检出可能延迟,临床监测中需注意。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

QUESTION ADDRESSED BY THE STUDY: Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA. Whether MTX exposure increases the risk of ILD in patients with RA is disputed. We aimed to evaluate the association of prior MTX use with development of RA-ILD. METHODS: Through a case-control study design with discovery and international replication samples, we examined the association of MTX exposure with ILD in 410 patients with chronic fibrotic ILD associated with RA (RA-ILD) and 673 patients with RA without ILD. Estimates were pooled over the different samples using meta-analysis techniques. RESULTS: Analysis of the discovery sample revealed an inverse relationship between MTX exposure and RA-ILD (adjusted OR 0.46, 95% CI 0.24-0.90; p=0.022), which was confirmed in the replication samples (pooled adjusted OR 0.39, 95% CI 0.19-0.79; p=0.009). The combined estimate using both the derivation and validation samples revealed an adjusted OR of 0.43 (95% CI 0.26-0.69; p=0.0006). MTX ever-users were less frequent among patients with RA-ILD compared to those without ILD, irrespective of chest high-resolution computed tomography pattern. In patients with RA-ILD, ILD detection was significantly delayed in MTX ever-users compared to never-users (11.4±10.4 years and 4.0±7.4 years, respectively; p<0.001). ANSWER TO THE QUESTION: Our results suggest that MTX use is not associated with an increased risk of RA-ILD in patients with RA, and that ILD was detected later in MTX-treated patients.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021. PMID: 32646919. doi:10.1183/13993003.00337-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。